p38 MAPK Inhibitors Ameliorate Target Organ Damage in Hypertension: Part 1. p38 MAPK-Dependent Endothelial Dysfunction and Hypertension

Journal of Pharmacology and Experimental Therapeutics

Volumn 307, Issue 3, 2003, Pages 932-938

  Ju, Haisong ^a   Behm, David J ^a   Nerurkar, Sandyha ^a   Eybye, Marianne E ^a   Haimbach, Robin E ^a   Olzinski, Alan R ^a   Douglas, Stephen A ^a   Willette, Robert N ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1,3 DIHYDROXYPROP 2 YL) 4 (4 FLUOROPHENYL) 5 (2 PHENOXYPYRIMIDIN 4 YL)IMIDAZOLE; 1 (4 HYDROXYCYCLOHEXYL) 4 (4 FLUOROPHENYLMETHOXYPYRIMIDIN 4 YL)IMIDAZOLE; 4 [4 (4 FLUOROPHENYL) 5 (2 METHOXY 4 PYRIMIDINYL) 1 IMIDAZOLYL]CYCLOHEXANOL; CARBACHOL; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NORADRENALIN; SB 239063AN; SODIUM CHLORIDE; SODIUM NITRATE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL REACTIVITY; CHEMICAL STRUCTURE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; HYPERTENSION; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; TARGET ORGAN; TELEMETRY;

ALBUMINURIA; ANIMALS; BLOOD PRESSURE; BLOTTING, WESTERN; CARBACHOL; CELL ADHESION MOLECULES; CEREBROVASCULAR ACCIDENT; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; HUMANS; HYPERTENSION; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; MUSCARINIC AGONISTS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIMIDINES; RATS; RATS, INBRED SHR; SURVIVAL; TELEMETRY;

EID: 0344304814     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.057422     Document Type: Article

References (29)

1. Barone FC, Nelson AH, Ohlstein EH, Willette RN, Sealey JE, Laragh JH, Campbell WG Jr, and Feuerstein GZ (1996) Chronic carvedilol reduces mortality and renal damage in hypertensive stroke-prone rats. J Pharmacol Exp Ther 279:948-955.
2. Barone FC, Coatney RW, Chandra S, Sarkar SK, Nelson AH, Contino LC, Brooks DP, Campbell WG Jr, Ohlstein EH, and Willette RN (2001) Eprosartan reduces cardiac hypertrophy, protects heart and kidney and prevents early mortality in severely hypertensive stroke-prone rats. Cardiovasc Res 50:525-537.
3. Behm DJ, Herold CL, Ohlstein EH, Knight SD, Dhanak D, and Douglas SA (2002) Pharmacological characterization of SB-710411 (Cpa-c[D-Cys-Pal-D-Trp-Lys-Val-Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist. Br J Pharmacol 137:449-458.
4. Behr TM, Nerurkar SS, Nelson AH, Coatney RW, Woods TN, Sulpizio A, Chandra S, Brooks DP, Kumar S, Lee JC, et al. (2001) Hypertensive end-organ damage and premature mortality are p38 mitogen-activated protein kinase-dependent in a rat model of cardiac hypertrophy and dysfunction. Circulation 104:1292-1298.
5. Griffin KA, Churchill PC, Picken M, Webb RC, Kurtz TW, and Bidani AK (2001) Differential salt-sensitivity in the pathogenesis of renal damage in SHR and stroke prone SHR. Am J Hypertens 14:311-320.
6. Hamilton CA, Brosnan MJ, McIntyre M, Graham D, and Dominiczak AF (2001) Superoxide excess in hypertension and aging: a common cause of endothelial dysfunction. Hypertension 37:529-534.
7. Huot J, Houle F, Marceau F, and Landry J (1997) Oxidative stress-induced actin reorganization mediated by the p38 mitogen-activated protein kinase/heat shock protein 27 pathway in vascular endothelial cells. Circ Res 80:383-392.
8. Ju H, Nerurkar S, Sauermelch CF, Olzinski AR, Mirabile R, Zimmerman D, Lee JC, Adams J, Sisko J, Berova M., et al. (2002) Sustained activation of p38 mitogen-activated protein kinase contributes to the vascular response to injury. J Pharmacol Exp Ther 301:15-20.
9. Kim I, Moon SO, Park SK, Chae SW, and Koh GY (2001) Angiopoietin-1 reduces VEGF-stimulated leukocyte adhesion to endothelial cells by reducing ICAM-1, VCAM-1 and E-selectin expression. Circ Res 89:477-479.
10. Kinlay S, Libby P, and Ganz P (2001) Endothelial function and coronary artery disease. Curr Opin Lipidol 12:383-389.
11. Landmesser U and Harrison DG (2001) Oxidative stress and vascular damage in hypertension. Coron Artery Dis 12:455-461.
12. Lenda DM and Boegehold MA (2002a) Effect of a high salt diet on microvascular antioxidant enzymes. J Vasc Res 39:41-50.
13. Lenda DM and Boegehold MA (2002b) Effect of a high-salt diet on oxidant enzyme activity in skeletal muscle microcirculation. Am J Physiol 282:H395-H402.
14. Lenhard SC, Nerurkar SS, Schaeffer TR, Mirabile RC, Boyce RW, Adams DF, Jucker BM, and Willette RN (2003) p38 MAPK inhibitors ameliorate target organ damage in hypertension: Part 2. Improved renal function as assessed by dynamic contrast-enhanced magnetic resonance imaging. J Pharmacol Exp Ther 307:xxx-xxx.
15. Liu Y, Rusch NJ, and Lombard JH (1999) Loss of endothelium and receptor-mediated dilation in pial arterioles of rats fed a short-term high salt diet. Hypertension 33:686-688.
16. Ma XL, Gao F, Nelson AH, Lopez BL, Christopher TA, Yue TL, and Barone FC (2001) Oxidative inactivation of nitric oxide and endothelial dysfunction in stroke-prone spontaneous hypertensive rats. J Pharmacol Exp Ther 298:879-885.
17. Pietersma A, Tilly BC, Gaestel M, de Jong N, Lee JC, Koster JF, and Sluiter W (1997) p38 mitogen activated protein kinase regulates endothelial VCAM-1 expression at the post-transcriptional level. Biochem Biophys Res Commun 230:44-48.
18. Raitakari OT and Celermajer DS (2000) Testing for endothelial dysfunction. Ann Med 32:293-304.
19. Read MA, Whitley MZ, Gupta S, Pierce JW, Best J, Davis RJ, and Collins T (1997) Tumor necrosis factor alpha-induced E-selectin expression is activated by the nuclear factor-kappaB and c-JUN N-terminal kinase/p38 mitogen-activated protein kinase pathways. J Biol Chem 272:2753-2761.
20. Ross R (1999) Atherosclerosis-an inflammatory disease. N Engl J Med 340:115-126.
21. Schiffrin EL (2002) Beyond blood pressure: the endothelium and atherosclerosis progression. Am J Hypertens 15:115S-122S.
22. Shimokawa H (1999) Primary endothelial dysfunction: atherosclerosis. J Mol Cell Cardiol 31:23-37.
23. Tamura DY, Moore EE, Johnson JL, Zallen G, Aiboshi J, and Silliman CC (1998) p38 mitogen-activated protein kinase inhibition attenuates intercellular adhesion molecule-1 up-regulation on human pulmonary microvascular endothelial cells. Surgery 124:403-407.
24. Touyz RM (2003) The role of angiotensin II in regulating vascular structural and functional changes in hypertension. Curr Hypertens Rep 5:155-164.
25. Touyz RM, He G, El Mabrouk M, and Schiffrin EL (2001) p38 Map kinase regulates vascular smooth muscle cell collagen synthesis by angiotensin II in SHR but not in WKY. Hypertension 37:574-580.
26. Verma S and Anderson TJ (2002) Fundamentals of endothelial function for the clinical cardiologist. Circulation 105:546-549.
27. Wilcox CS (2002) Reactive oxygen species: roles in blood pressure and kidney function. Curr Hypertens Rep 4:160-166.
28. Yamashita T, Taka T, Nojima R, Ohta Y, Seki J, and Yamamoto J (2002) There is no valid evidence presented as to an impaired endothelial NO system in the stroke-prone spontaneously hypertensive rats. Thromb Res 105:507-511.
29. Zhu Y, Liao H, Wang N, Ma KS, Verna LK, Shyy JY, Chien S, and Stemerman MB (2001) LDL-activated p38 in endothelial cells is mediated by Ras. Arterioscler Thromb Vasc Biol 21:1159-1164.